Funds holding RANI THERAPEUTICS HOLDINGS INC
ISIN US7530181004 · United States
- Fund holders
- 14
- Of which ETFs
- 1 13 other funds
- Value held
- ≈ 4.6M $ 4.2M $ · 281.8K €
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3,646,699 | 2.8M $ | 0.00 % | as of Jun 30, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 834,894 | 634.9K $ | 0.00 % | as of Jun 30, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 402,359 | 382.6K $ | 0.00 % | as of May 31, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 138,177 | 131.4K $ | 0.00 % | as of May 31, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 115,378 | 109.7K $ | 0.00 % | as of May 31, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 114,500 | 87.1K $ | 0.06 % | as of Jun 30, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 61,920 | 58.9K $ | 0.00 % | as of May 31, 2026 ↗ |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 49,891 | 37.9K $ | 0.00 % | as of Jun 30, 2026 ↗ |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 31,501 | 24K $ | 0.00 % | as of Jun 30, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 5,139 | 4.9K $ | 0.01 % | as of May 31, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 3,608 | 3.4K $ | 0.00 % | as of May 31, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 479 | 370.8 $ | 0.00 % | as of Jul 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 172.3K € | 0.21 % | as of Dec 31, 2025 ↗ | |
| ABANTE QUANT VALUE, F.I. ABANTE ASESORES GESTION, SGIIC, S.A. | 109.4K € | 0.58 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| ABANTE QUANT VALUE, F.I. ABANTE ASESORES GESTION, SGIIC, S.A. | 0.58 % | as of Dec 31, 2025 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 0.21 % | as of Dec 31, 2025 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 0.06 % | as of Jun 30, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 0.01 % | as of May 31, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 0.00 % | as of May 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Jun 30, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 12 | -3 | 5,404,545 | -4.8 % |
| 2026Q2 | 15 | +3 | 5,674,342 | +7.3 % |
| 2026Q1 | 12 | +2 | 5,287,296 | +473.0 % |
| 2025Q4 | 10 | -1 | 922,667 | -14.3 % |
| 2025Q3 | 11 | +1 | 1,076,805 | +6.2 % |
| 2025Q2 | 10 | -2 | 1,013,679 | -2.9 % |
| 2025Q1 | 12 | +1 | 1,043,836 | +11.4 % |
| 2024Q4 | 11 | +1 | 937,348 | +2.9 % |
| 2024Q3 | 10 | +1 | 910,633 | +6.2 % |
| 2024Q2 | 9 | -2 | 857,521 | +3.6 % |
| 2024Q1 | 11 | -1 | 827,756 | +1.8 % |
| 2023Q4 | 12 | 812,879 |
Institutional managers
69 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 8,500,000 | 6.2M $ | as of Mar 31, 2026 |
| SAMSARA BIOCAPITAL, LLC | 8,500,000 | 6.2M $ | as of Mar 31, 2026 |
| AWM Investment Company, Inc. | 6,500,000 | 4.8M $ | as of Mar 31, 2026 |
| SymBiosis Capital Partners, LLC | 3,667,585 | 2.7M $ | as of Mar 31, 2026 |
| Longaeva Partners L.P. | 2,329,459 | 1.7M $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 2,000,000 | 1.5M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 903,298 | 664.1K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 556,889 | 409.2K $ | as of Mar 31, 2026 |
| Nan Fung Group Holdings Ltd | 493,584 | 362.7K $ | as of Mar 31, 2026 |
| 683 Capital Management, LLC | 487,168 | 358K $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 405,669 | 298.1K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 373,142 | 274.2K $ | as of Mar 31, 2026 |
| UNITED SERVICES AUTOMOBILE ASSOCIATION | 302,743 | 222.5K $ | as of Mar 31, 2026 |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 265,159 | 194.8K $ | as of Mar 31, 2026 |
| UBS Group AG | 227,223 | 167K $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 188,222 | 138.3K $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 170,471 | 125.3K $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 165,599 | 121.7K $ | as of Mar 31, 2026 |
| Hudson Bay Capital Management LP | 153,331 | 112.7K $ | as of Mar 31, 2026 |
| CWA Asset Management Group, LLC | 150,000 | 110.2K $ | as of Mar 31, 2026 |
| Cygnus Capital Advisors, LLC | 115,649 | 85 $ | as of Mar 31, 2026 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 114,500 | 84.1K $ | as of Mar 31, 2026 |
| GSA CAPITAL PARTNERS LLP | 96,998 | 71 $ | as of Mar 31, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | 78,000 | 57.3K $ | as of Mar 31, 2026 |
| OMERS ADMINISTRATION Corp | 76,500 | 56.2K $ | as of Mar 31, 2026 |
Declared shareholders of RANI THERAPEUTICS HOLDINGS INC
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| RA Capital Management, L.P. and 3 others | 9.90 % | 11,530,414 | as of Jun 30, 2026 · SCHEDULE 13G |
| Vanguard Capital Management | 4.49 % | 5,052,862 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding RANI THERAPEUTICS HOLDINGS INC". https://titelia.com/en/stocks/rani-therapeutics-holdings-inc-US7530181004